How should Leber hereditary optic neuropathy (LHON) be diagnosed and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Leber Hereditary Optic Neuropathy (LHON): Diagnosis and Management

LHON should be diagnosed through genetic testing for the three common mitochondrial DNA mutations (m.11778G>A, m.14484T>C, m.3460G>A) in any patient presenting with bilateral, painless, subacute vision loss, particularly young males aged 15-30 years, and treated immediately with idebenone when diagnosed within the first year of vision loss. 1, 2

Clinical Presentation and When to Suspect LHON

LHON typically manifests as:

  • Bilateral, painless, subacute central vision loss in young adults (peak onset 15-30 years, though can occur at any age from 2-81 years) 3, 2
  • Male predominance (4:1 male-to-female ratio) 2
  • Sequential eye involvement in 50-75% of cases, with the second eye affected 2-3 months after the first 2
  • Rapid deterioration to counting fingers or worse with dense central or centrocecal scotoma 2

Critical diagnostic clue: The absence of ocular pain distinguishes LHON from inflammatory optic neuritis, which is the most common misdiagnosis 4, 5.

Diagnostic Workup

Ophthalmologic Examination

In the acute/subacute phase, look for:

  • Hyperemic optic disc with peripapillary retinal nerve fiber layer swelling
  • Peripapillary telangiectasias
  • Increased vascular tortuosity
  • Dense central or centrocecal scotoma
  • Visual acuity deterioration to counting fingers or worse 2

Optical Coherence Tomography (OCT)

Marked thinning of the ganglion cell complex is present even in the subacute phase and helps distinguish LHON from inflammatory optic neuritis 4, 2.

Neuroimaging (MRI)

While not required for diagnosis, MRI findings when present include:

  • T2-hyperintensity of optic nerves and/or chiasm (22.6% of cases, more common in females) 3
  • Postcontrast enhancement of optic nerves and/or chiasm (10.9% of cases, more common in females) 3
  • Optic chiasm enlargement (5.1%) or atrophy (13.1%) 3
  • Rarely, transient spinal cord lesions (LHON-plus syndrome) 6

Important caveat: Normal neuroimaging does not exclude LHON. Imaging is useful primarily to exclude demyelinating diseases when the diagnosis is uncertain 3, 4.

Genetic Testing - The Definitive Diagnostic Step

Step 1: Test for the three most common pathogenic mtDNA mutations first:

  • m.11778G>A in MT-ND4 (most common worldwide, most severe variant)
  • m.14484T>C
  • m.3460G>A

These account for >90% of LHON cases 7, 1, 8.

Step 2: If initial testing is negative but clinical suspicion remains high, proceed to comprehensive mtDNA sequencing 4, 1.

Step 3: Consider whole-genome sequencing or clinical exome analysis to identify nuclear modifiers that influence phenotype 9.

Management and Treatment

Idebenone - The Only Approved Treatment

Idebenone (synthetic CoQ10 analog) is approved by the European Medicines Agency and should be initiated immediately upon diagnosis, particularly within the first year of vision loss onset. 1, 2, 8

Mechanism: Improves mitochondrial electron transport and reduces oxidative stress 9.

Evidence: Current data shows some benefit to vision in a subset of patients, with best outcomes when treatment begins within the first year of vision loss 1, 2.

Dosing and administration details: While the consensus statement 1 provides guidelines, specific dosing should follow approved prescribing information.

Emerging Therapies

Gene therapy using rAAV2/2-ND4 (allotopic expression of ND4) has shown promise in clinical trials (RESTORE and REFLECT), with improvement in both eyes even after unilateral injection 9.

Advanced gene-editing techniques (zinc finger nucleases, TALENs) are under investigation for correcting heteroplasmic mutations 9.

Supportive Management

  • Avoid environmental triggers: Smoking cessation is critical, as environmental factors play a crucial role in triggering LHON and determining severity 8
  • Genetic counseling: Essential given maternal inheritance pattern
  • Low vision rehabilitation: For patients with permanent vision loss
  • Family screening: Test at-risk maternal relatives, as they may carry mutations asymptomatically

Common Pitfalls to Avoid

  1. Misdiagnosing as inflammatory optic neuritis: The absence of pain and lack of response to corticosteroids should prompt genetic testing 4, 5

  2. Delaying genetic testing: Do not wait for bilateral involvement—test when unilateral painless vision loss occurs in the appropriate demographic 4, 1

  3. Assuming normal MRI excludes LHON: Neuroimaging is often normal; diagnosis relies on clinical presentation and genetic confirmation 3, 4

  4. Missing the treatment window: Idebenone is most effective when started within the first year of vision loss 1, 2

  5. Overlooking LHON-plus syndrome: Some patients have additional neurological manifestations including transient spinal cord lesions that may mimic demyelinating disease 6

Prognosis

The m.11778G>A mutation carries the worst prognosis, while m.14484T>C has the best chance of spontaneous recovery 8. However, most patients experience permanent, substantial central vision loss without treatment 2, 9. Early diagnosis and treatment with idebenone offer the best opportunity for visual recovery.

References

1
Research

International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2017

5
Research

[Considering Leber´s hereditary optic neuropathy].

MMW Fortschritte der Medizin, 2023

8
Research

[Leber's hereditary optic nerve atrophy].

Vestnik oftalmologii, 2026

Related Questions

In a 73‑year‑old female with recent finger release surgery who now has finger pain and numbness, what diagnostic tests should be performed to evaluate the cause?
In a 50-year-old man on statin therapy with normal total cholesterol and markedly elevated triglycerides (~5.3 mmol/L) and no history of cardiovascular disease, diabetes, or hypertension, what is the most appropriate next step in management?
Why would one take exogenous D‑β‑hydroxybutyrate (Original Ketone®) despite its temporary suppression of endogenous ketogenesis, and how many hours after a typical dose does endogenous ketone production resume?
In a 14‑week pregnant woman with a headache unresponsive to fluids and rest, what are the differential diagnoses and appropriate treatment options?
How can exogenous ketone supplements stimulate endogenous ketone production?
Is there a blood test for bacterial vaginosis or trichomoniasis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.